Prime Medicine (PRME) Cash from Financing Activities (2021 - 2026)

Prime Medicine (PRME) has 6 years of Cash from Financing Activities data on file, last reported at $393000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 93.45% year-over-year to $393000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.9 million (up 227.52% YoY) and the FY2025 annual result came in at $151.5 million, down 22.65% from the prior year.
• Cash from Financing Activities eased to $393000.0 in Q1 2026, from $562000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $184.1 million in Q4 2022 to a low of -$1.3 million in Q1 2022.
• A 5-year average of $31.2 million and a median of $197000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 99.89% — and 2024, when it soared 231263.24%.
• Tracing PRME's Cash from Financing Activities over 5 years: stood at $184.1 million in 2022, then slumped by 99.89% to $194000.0 in 2023, then plunged by 99.48% to $1000.0 in 2024, then soared by 56100.0% to $562000.0 in 2025, then plunged by 30.07% to $393000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $393000.0 (Q1 2026), $562000.0 (Q4 2025), and $144.8 million (Q3 2025), per Business Quant data.